Gavi s Sustainability and Transition Approach

Similar documents
GAVI, THE VACCINE ALLIANCE

Gavi s private sector engagement approach

Gavi s strategic framework 22 June 2016

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

Gavi Alliance Strategy : Goal level indicators and disease dashboard

Report to the Board June 2016

Report to the Board 6-7 June 2018

Managing the Gavi transition

1. The World Bank-GAVI Partnership and the Purpose of the Review

Gavi Secretariat Update: Progress, priorities and strategies

GAVI, THE VACCINE ALLIANCE

GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL

Report to the. GAVI Alliance Board June 2014

Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance

Report to the. GAVI Alliance Board June 2013

GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS

Update from Gavi, the Vaccine Alliance

REVIEW OF DECISIONS. BOARD MEETING 6-7 June 2018, Geneva. Reach every child

Report to the Board June 2016

Gavi Risk Appetite Statement Version 2.0

Access to vaccination in GAVI countries and at global level

GAVI RESOURCE GAP ALWAYS BEEN AN ISSUE

Gavi initiatives for improving vaccine supply

Meeting the MDGs in South East Asia: Lessons. Framework

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE

The Financial Sustainability of New Vaccine Introduction in the Poorest Countries :

COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)

GAVI Alliance Board Meeting, 30 November 1 December 2010 Updates

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013

HPV Vaccine Lessons Learned & New Ways Forward

Analysis of indicators used in Financial Sustainability Plans submitted to GAVI

Sustainable VMMC Programmes: Frameworks for Diagnosing and Improving Program Sustainability. Marelize Gorgens The World Bank

INVESTING IN A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

Information for Access

within three to six months of the launch of a new vaccine.

Innovative Finance: the power of innovation to save lives

HPV Demonstration Programme Update and initial lessons learnt on programme design. HPV Subteam Geneva, Switzerland June 17, 2014

UPDATE ON GAVI. Julian Lob-Levyt. Global Immunisation Meeting New York, February 2009

Vaccine Pricing: Gavi Transitioning Countries

GAVI 5.0 THE ALLIANCE S STRATEGY

Rotavirus Vaccine. Supply and Procurement Roadmap. The Market Shaping Goal. Public Summary. Rotavirus Supply and Procurement Roadmap UPDATE 2016

GAVI Secretariat response to the IFFIm evaluation

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

Meeting Nigeria s vaccines financing needs ( )

Report to the. GAVI Alliance Board November 2013

Report to the Board 7-8 December 2016

Government of Bangladesh

Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets

Report to the Board 7-8 December 2016

Gavi s Vaccine Investment Strategy

What is this document and who is it for?

A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA

2018 INFUSE CALL FOR INNOVATION

Gavi, the Vaccine Alliance Co-financing Policy Version 2.0

The Global Fund & UNICEF Partnership

Update from GAVI Aurelia Nguyen

TOGETHER Quick start guide for

The use of total funds channelled through "la Caixa" to Gavi programmes in 2017

Appendix A. GAVI: Purpose, Contributions, and Activities

Cancer prevention and control in the context of an integrated approach

Global Health Policy: Vaccines

GAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013

Cross-cutting HSS (Health Systems Strengthening): Experience from WPRO

Executive Board of the United Nations Development Programme, the United Nations Population Fund and the United Nations Office for Project Services

What is to be done to respond to country needs and comply with WHA and SAGE recommendations?

used for HPV vaccine delivery to identify best practices and inform efforts to improve HPV vaccine coverage nationwide.

Report to the. GAVI Alliance Board June Alan Brooks, Special Adviser for Immunisation

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

2014 PARTNERSHIP PROFILE: The GAVI Alliance

GAVI Role in IPV Introductions

TALKING POINTS INTRODUCTION

New GFF-IBRD Partnership to Leverage Private Sector Investments for Maternal, Child and Adolescent Health

GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment

Monitoring of the achievement of the health-related Millennium Development Goals

PARTNERSHIP PROFILE: GAVI

Aboubacar Kampo Chief of Health UNICEF Nigeria

Saving lives through immunisation A Corporate Social Responsibility approach

TYPHOID CONJUGATE VACCINE SUPPORT WINDOW

Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development

WHO Update Tania Cernuschi & Patrick Lydon

GAVI, THE VACCINE ALLIANCE

Presentation to 13th Annual General Meeting of the DCVMN UNICEF Vaccine Forecasting

Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues

Executive Board of the United Nations Development Programme, the United Nations Population Fund and the United Nations Office for Project Services

STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF

DEVELOPING A GLOBAL IMMUNIZATION STRATEGY

CEO Board report Seth Berkley MD CEO

The Strategy Development Process. Global Fund and STOP TB Consultation Istanbul, Turkey 24 July 2015

Gavi Unicef Vaccine Industry Consultation. Dominic Hein Market Shaping / Gavi. October Reach every child

ADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA

Perspectives on Ensuring Access to Vaccines in Lower Income Countries

The Global Financing Facility in Support of Every Woman Every Child

REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

CEO Board update. Seth Berkley, MD 14 June 2017, Geneva.

MARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA

Report to the Board June 2015

Report to the Board June 2016

Report to the Board 6-7 June 2018

Transcription:

Gavi s Sustainability and Transition Approach Santiago Cornejo Director, Immunisation Financing and Sustainability 13 June 2018 www.gavi.org

Countries tend to face various programmatic and financing challenges at different development stages Schematic representation of main programmatic and financing bottlenecks to immunisation along the development continuum Weaker health and immunisation system foundations Acute fiscal constraints Stronger systems but with institutional capacity gaps in key areas Growing domestic resources, but inadequate allocative efficiency and prioritization Some gains at risk Missed opportunities for broader impact and efficiencies Income per capita These are not absolute categories: actual country realities sit somewhere on this continuum First wave of transitioning countries aligned with this model

Evolving needs require evolving types of engagement and support Early engagement: Building foundations for sustainability Post-transition Health systems and immunisation strengthening (HSIS) Targeted Country Assistance (TCA) Fixed, low cofinancing level Health systems and immunisation strengthening, but diminishing support for recurrent costs TCA / Transition grants Growing co-financing requirements Targeted support to mitigate post transition risks and support continued transformation and pricing Preparing for transition

Eligibility, transition and co-financing policies provide the institutional framework for Gavi s engagement WB Low-Income country threshold $1,005 GNI pc Eligibility threshold: $1,580 GNI pc variable duration variable duration 5 years years Low-income country threshold Eligibility threshold End of Gavi financing

Country co-financing level and serve as key mechanism for domestic resource mobilization and financial sustainability WB Low-Income country threshold $1,005 GNI pc Accelerated transition Eligibility threshold: $1,580 GNI pc Fully self financing 100% of vaccine cost Preparatory transition Initial self financing variable duration variable duration 5 years years Low-income country threshold Eligibility threshold End of Gavi financing

Gavi s sustainability approach: key components Financial and programmatic sustainability: Domestic financing is key, but it is not enough Programmatic sustainability requires critical national capacities, e.g., capacity for planning and budgeting, capacity to procure vaccines at competitive prices, etc. Integrate sustainability in the design of Gavi s engagement with countries Getting the sequencing of interventions right is key: Addressing systemic bottlenecks early on Adapting support to needs and reflecting the transition status: No support for recurrent costs in the last phase of transition Leveraging existing systems where possible and needed 6

16 countries have already transitioned and 9 countries are still in transition 7

Before and after Gavi: DTP3 coverage DTP3 coverage comparing 2016 to 1999 Immunisation coverage (%): Before Gavi support (1999) Latest coverage data available (2016) (Source: WEUNIC, 2016) 8

Before and after Gavi: new vaccine introductions (Pentavalent, PCV, Rotavirus, HPV, up to 2017) 9

Before and after Gavi: government expenditures on routine immunisation (US$ per child on immunisation comparing pre & post transition) Annual financing by country per child (US$): Amount on pretransition year, different for each country Latest amount data available (2017, includes selffinanced programme amounts) 10

Findings on transition observed so far 1. Immunisation financing: fiscal space does not seem to be the main challenge in most of the first-wave countries Critical issues are weak planning, budgeting and execution processes and broader financing of the sector 2. Programme performance: generally high coverage programmes, but important capacity gaps were observed on vaccine introductions Also a subset with low coverage (e.g. PNG, Congo Rep, Nigeria, Angola) 3. Institutional capacities: critical gaps and areas for strengthening (e.g., regulation, procurement, supply chains, data systems)

Findings on transition observed so far 4. Common concerns about losing supportive environment that is associated with being part of the Alliance Anti-vaccination lobby Technical assistance post-gavi Prioritisation of immunisation 5. Greater realisation that engagement with sub-national levels is critical for sustainable coverage and equity, which requires engagement with a wide range of stakeholders Within the ministry of health and across ministries (e.g. MoF) National and subnational authorities and parliamentarians Across external partners (e.g. The World Bank, Global Fund) Civil society, communities and private sector 12

Gavi s extensive partnership with private sector FINANCIAL CONTRIBUTION LEVERAGED INVESTMENT PARTNERSHIP SHARED VALUE PARTNERSHIP FINANCING PRIVATE SECTOR AND FUNDIND MECHANISMS EXPERTISE Single or multiyear financial pledge in support of Gavi programmes that may be matched by Matching Fund (e.g. corporate or foundation philanthropic support, INFUSE Pacesetters) Financial pledge accompanied by corporate expertise or programmatic intervention with potential match by Matching Fund (e.g. demand generation, INFUSE Pacesetters) Co-investment by the partner and Gavi core funding to develop a sustainable, scalable solution (e.g. supply chain services, data management systems, INFUSE Pacesetters)

Gavi s extensive partnership with private sector PRIVATE SECTOR PARTNERSHIPS CAN PLAY A GREATER ROLE IN TRANSITION Supply Chain Data Management Demand Generation

Important lessons Sustainability has two components: financial and programmatic Early engagement and planning Addressing health systems bottlenecks and institutional constraints Progressive phasing out of support Provide predictability and transparency Flexibility to adapt and adjust approach (Evolving or learning agenda) There is no silver bullet: getting the basics right is key There is no substitute for appropriate regular planning, budgeting, disbursement and execution Prioritization, prioritization and prioritization Wide-ranging inclusion of stakeholders 15

THANK YOU www.gavi.org

Gavi s theory of change Supporting the country s population to be healthier and more productive generates greater prosperity for the country, enabling it to finance its primary health programmes 17

Partnering with the private for innovation scale up Developed using Gates Grand Challenge grant supported by the BMGF Scaled deployment 13,000 ColdTrace devices across India with Gavi HSS Accelerated by INFUSE, through support from Google.org and Elma matched by the Gavi Matching Fund 2013 Pilot in Haiti and Kenya 2015-2017 Deployment across 12 states in India as part of evin 2016-2018 Scaling across Tanzania, Kenya, Mozambique and Senegal 18